Platelets and thrombosis in myeloproliferative diseases.
The myeloproliferative disorders have been the "poor cousins" in the family of hematological malignancies for some time. Recently this field has advanced considerably with the description of a mutation in the JAK2 kinase detectable in the majority of patients and the publication of two landmark clinical trials--ECLAP and MRC PT1. But although both ECLAP and MRC PT1 inform clinical management and allude to the complexities of thrombosis we still lack fundamental knowledge, and our understanding of thrombosis in these conditions has not paralleled advances in the field of thrombosis and vascular biology. The predominant clinical complications of essential thrombocythemia and polycythemia vera are thrombotic and hemorrhagic; these significantly impact upon prognosis and quality of life. Here the current status of our knowledge is reviewed with specific emphasis upon the role of the platelet in the pathogenesis of thrombosis as well as the impact of recent data from ECLAP and MRC PT1.
Harrison
Claire N
CN
Thomas' Hospital, Lambeth Palace Road, London, England SE1 7EH, United Kingdom. claire.harrison@gstt.sthames.nhs.uk
D001241:Aspirin / Q000627:therapeutic use; D001792:Blood Platelets / Q000502:physiology*; D002986:Clinical Trials as Topic; D004730:Endothelium, Vascular / Q000503:physiopathology; D006400:Hematocrit; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000150:complications; D007962:Leukocytes / Q000502:physiology; D009196:Myeloproliferative Disorders / Q000097:blood* / Q000235:genetics; D015539:Platelet Activation; D011087:Polycythemia Vera / Q000097:blood / Q000150:complications; D013917:Thrombin / Q000502:physiology; D013927:Thrombosis / Q000097:blood* / Q000209:etiology* / Q000517:prevention & control
C507924:JAK2 protein, human; D053614:Janus Kinase 2; D013917:Thrombin; D001241:Aspirin